This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • Genomic Biomarker Testing
      • PEACE-3 Trial
      • PROfound Trial
      • PSMAfore Trial
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • VISION Trial
    • mHSPC
      • ARANOTE Trial
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • nmCSPC
      • EMBARK Trial
    • PSMA PET Imaging
      • COBRA Trial
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
      • BOND-003 Cohort P
      • CORE-001 Study
      • CORE-008
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Daniel D. Joyce, MD, MS
        • Bladder Cancer
          • Non-Muscle Invasive Bladder Cancer
            Ashish Kamat, MD
          • Muscle-Invasive Bladder Cancer
          • Advanced & Metastatic Bladder Cancer (mUC)
          • Trimodality Therapy
            Leslie Ballas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
        • Endourology
          • Endourology
            Jaime Landman, MD
      • Prostate Cancer
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • Decipher® Genomic Classifier
        • Imaging Center
          Phillip Koo, MD
        • mHSPC
          Neeraj Agarwal, FASCO, MD
        • nmCRPC
          Zachary Klaassen, MD, MSc
        • mCRPC Treatment
          A. Oliver Sartor, MD
        • mCRPC with Bone Metastasis
        • PSMA-Targeted Therapy
        • Advanced Prostate Cancer
          Zachary Klaassen, MD, MSc
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • Testicular, Penile & Rare GU Malignances
        • Testicular Cancer
    • Functional Urology
      • Functional Urology
        Alan J. Wein, MD, PhD (hon.)
      • Urologic Catheters - CAUTI Challenges
  • Videos
    • Exclusives
      • Conferences
      • Disparities: Social Determinants of Health
      • Exclusive Collaborations
      • Health Policy in Urological Diseases
      • Independent Medical Education
      • Journal Clubs
      • Practice Guidelines Reviews
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Testicular Cancer
      • Endourology
    • Functional Urology
      • Men's Health
      • Pelvic Health
  • Actionable Clinical Data
    • Bladder Cancer
      • NMIBC with CIS: Evidence, Practice & Emerging Research
      • Risk-Stratified NMIBC Management
  • Trials in Progress
    • Prostate Cancer
      • Localized Prostate Cancer
        • CLARIFY
        • ESCAPE
        • FORT
        • NRG-GU 0101
        • RTIRE
      • High Risk BCR HSPC
        • ARASTEP
      • Oligometastatic Prostate Cancer
        • METANOVA
      • mHSPC
        • ARASEC
        • ASPIRE
        • MEVPRO-3
      • mCRPC
        • ECLIPSE
        • LEGION-100
        • MEVPRO-1 & 2
        • PROMISE
        • SECuRE
    • Bladder Cancer
      • PIVOT-006
    • Kidney Cancer
      • RadiCal
      • SAMURAI
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SNMMI 2026
      • ASCO 2026
      • AUA 2026
      • APCCC 2026
      • PSMA and Beyond 2026
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Conference Highlights

AUA Congress 2022

AUA 2022 Prostate Cancer

  • AUA 2022: 68 Ga-PSMA PET/CT for Preoperative Lymph Node Staging of High Risk Prostate Cancer
  • AUA 2022: Can Pelvic Lymph Node Dissection Be Omitted at the Time of Radical Prostatectomy in Patients With a Negative Preoperative 68Ga-PSMA PET/CT? The Importance of Patient Risk Stratification According to Individual Risk of Lymph Node Metastases
  • AUA 2022: The Impact Of Histological Variants On The Performance Characteristics Of 68Ga-PSMA PET/CT In The Primary And Recurrent Setting
  • AUA 2022: Newer Robots, Smaller Robots, Cheaper Robots—Where Is the Technology Headed?
  • AUA 2022: Negative Prostate MRI as a Predicator of Disease Stability in Patients With Active Surveillance
View all (91 articles)

AUA 2022 Bladder Cancer

  • AUA 2022: Surrogate Endpoints as Predictors of Survival in Metastatic Urothelial Cancer Trials
  • AUA 2022: Frequency of Fibroblast Growth Factor Receptor Alterations and Association With Bacillus Calmette-Guerin Outcomes in a Real-World Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) Study
  • AUA 2022: Longitudinal Health-Related Quality of Life Outcomes in Adults with Non-Muscle-Invasive Bladder Cancer Receiving a Chemoablative Gel as a Primary Treatment (Optima II: Phase 2b, single arm, open-label trial)
  • AUA 2022: A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Recirculant Hyperthermic Intravesical Chemotherapy
  • AUA 2022: Neoadjuvant Pembrolizumab May Result in Long-Term Outcome Improvement in Biomarker-Unselected Patients With Muscle-Invasive Bladder Cancer: Updated results from PURE-01
View all (54 articles)

AUA 2022 Kidney Cancer

  • AUA 2022: Development of Patient-Derived Kidney Cancer Organoid; Application to Drug Screening Models and Its Challenges
  • AUA 2022: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma
  • AUA 2022: Machine Learning Approach to Predict pT3a Upstaging of Clinically Localized Renal Cell Carcinoma and Oncological Outcomes After Surgery (UroCCR 15 Study)
  • AUA 2022: Improved Prediction of Renal Function After Radical Nephrectomy
  • AUA 2022: Single Port Robotic Urologic Surgery: Fewer Ports, Higher Costs
View all (20 articles)

AUA 2022 Testicular and Penile Cancer

  • AUA 2022: Survival in N3 Penile Cancer: Does Pelvic Lymphadenopathy Predict a Worse Prognosis than Inguinal Extra-Nodal Extension?
  • AUA 2022: Concomitant vs Staged Lymphadenectomy in Clinically Node-Positive Penile Squamous Cell Carcinoma: Recurrence Patterns and Survival Outcomes
  • AUA 2022: Contemporary Surgical Outcomes of Retroperitoneal Lymph Node Dissection From the SEMS Trial
  • AUA 2022: Medium to Long Term Health-Related QoL and Treatment-Related Side-Effects in Patients Treated with a Single Dose of Adjuvant Carboplatin for High-risk Seminoma – Results From a Pilot Study
  • AUA 2022: Refinement of the Serum miR-371a-3p Test for the Detection of Chemotherapy-naive Minimal Residual Testicular Cancer
View all (7 articles)

AUA 2022 Press Release

  • Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
  • Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
  • Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
  • UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
  • Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
View all (14 articles)

AUA 2022 Stone Disease

  • AUA 2022: The Patient Voice: Experiences with Ureteral Stent Removal – A Urinary Stone Disease Research Network (USDRN) Study
  • AUA 2022: Determining the Threshold of Safety for Intrarenal Pressure During Flexible Ureteroscopy Using an in Vivo Pig Model
  • AUA 2022: A Prospective, Randomized, Single-Blind Study of Ureteral Stent Biomaterial Encrustation After Ureteroscopic Lithotripsy
  • AUA 2022: Predicting the Need for Intervention in Renal Colic Due to a Ureteral Stone
  • AUA 2022: Prevalence of 24-Hour Urine Abnormalities Among Older Adults with Urinary Stone Disease
View all (17 articles)
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2026 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free